[1]
|
Zheng, R.S., Chen, R., Han, B.F., et al. (2024) Cancer Incidence and Mortality in China, 2022. Chinese Journal of Oncology, 46, 221-231.
|
[2]
|
Matsui, Y., Hamada, M., Matsumi, Y., et al. (2022) Curative Resection of Ureteral Metastasis of Rectal Cancer: A Case Report and Review of Literature. Clinical Journal of Gastroenterology, 15, 151-156. https://doi.org/10.1007/s12328-021-01568-3
|
[3]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, No. 1. https://doi.org/10.3322/caac.21590
|
[4]
|
Siegel, R.L., Miller, K.D., Sauer, A.G., et al. (2020) Colorectal Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 145-164. https://doi.org/10.3322/caac.21601
|
[5]
|
中华人民共和国国家卫生和计划生育委员会. 直肠癌规范化诊疗指南(试行) [J]. 中国医学前沿杂志(电子版), 2013(7): 56-61.
|
[6]
|
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T. and Shitara, K. (2020) Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology, 38, JCO.19.03296. https://doi.org/10.1200/JCO.19.03296
|
[7]
|
Kuboki, Y., et al. (2017) TAS-102 plus Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (C-TASK FORCE): An Investigator-Initiated, Open-Label, Single-Arm, Multicentre, Phase 1/2 Study. The Lancet Oncology, 18, 1172-1181. https://doi.org/10.1016/S1470-2045(17)30425-4
|
[8]
|
Per, P., Mette, Y., Sören, M., et al. (2020) TAS-102 with or without Bevacizumab in Patients with Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial. The Lancet Oncology, 21, 412-420.
|
[9]
|
张泽群, 龙飞, 胡桂, 李小荣. 2021年V2版NCCN结肠癌临床实践指南更新解读[J]. 临床外科杂志, 2022, 30(1): 16-19.
|
[10]
|
姚宏伟, 刘荫华. NCCN结直肠癌临床实践指南2011年更新解读[J]. 中华胃肠外科杂志, 2011, 14(4): 5.
|
[11]
|
Qi, C., Gong, J., Li, J., et al. (2022) Claudin18.2-Specific CAR T Cells in Gastrointestinal Cancers: Phase 1 Trial Interim Results. Nature Medicine, 28, 1189-1198. https://doi.org/10.1038/s41591-022-01800-8
|
[12]
|
Almåsbak, H., Aarvak, T. and Vemuri, M.C. (2016) CAR T Cell Therapy: A Game Changer in Cancer Treatment. Journal of Immunology Research, 2016, Article 5474602. https://doi.org/10.1155/2016/5474602
|